Dalfoni Banerjee is an award-winning serial entrepreneur and consultant. Beginning her career over 30 years ago in academic, pharmaceutical, and start-up biotechnology research laboratories, she went on to lead inspection-readiness efforts at Merck & Co., Inc, drive clinical research and clinical operations, manage relationships between pharma and key opinion leaders, develop marketing strategies/tactics, and launch new drug products – across 12+ therapeutic categories. In 2011, Dalfoni founded, and continues to operate, 3Sixty Pharma Solutions, which has a mission to support start-up and established pharmaceutical, biotechnology, and medical device companies with subject-matter experts who help teams accelerate development, overcome challenges, and avoid preventable delays. In 2023, Dalfoni founded a biotechnology company focused on pioneering an innovative technology that rapidly generates antigens, primarily, for vaccines. Dalfoni is a mentor and trusted advisor to entrepreneurs, life-science organizations, start-up incubators, and university innovation and technology transfer offices, serves on Temple University’s iNest Board of Advisors, the Board of Directors for the Berks Innovation Collaborative, and the Merck Sharp & Dohme Federal Credit Union Board of Directors, is an invited speaker and moderator on a variety of industry-related topics, has authored and co-authored several publications, and has received over 30 awards.